The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
OBJECTIVE
Various novel therapies for spondyloarthritis (SpA) are currently under development. In this review, we discuss the scientific rational to target the interleukin (IL)-23/IL-17 axis in SpA and give an overview of the proof-of-concept trials with drugs directed towards this axis.


RESULTS
Cumulative evidence from genetics (e.g. the strong genetic association with the IL-23 receptor gene), in-vitro models (e.g. the increased IL-23 production upon HLA-B27 misfolding), human expression studies (e.g. the expansion of IL-17 producing innate cells in SpA) and animal models (e.g. the increased IL-17 production in HLA-B27 transgenic rats) strongly supports the involvement of the IL-23/IL-17 axis in the pathogenesis of SpA. Ustekinumab (a monoclonal antibody directed against the common p40 subunit of IL-23 and IL-12), secukinumab, ixekizumab (both monoclonal antibodies directed against IL-17A), and brodalumab a monoclonal antibody against the IL-17RA receptor) have been recently used in proof-of-concept and randomized trials in the ankylosing spondylitis and/or psoriatic arthritis subforms of SpA, with overall very promising clinical efficacy.


CONCLUSIONS
The first results for novel drugs blocking key cytokines in the IL-23/IL-17 axis are promising in SpA and more novel compounds are upcoming. This will teach us more on the role of the IL-23/IL-17 axis in the pathophysiology of SpA.
aDepartment of Clinical Immunology and Rheumatology bLaboratory of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Nataliya
N
Yeremenko
Jacqueline E
JE
Paramarta
Dominique
D
Baeten
D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism*; D053759:Interleukin-23 / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects* / Q000276:immunology; D025241:Spondylarthritis / Q000188:drug therapy* / Q000276:immunology
D018501:Antirheumatic Agents; D020381:Interleukin-17; D053759:Interleukin-23